|
|
By Anna Rose Welch, chief editor, Biosimilar Development
In this Q&A, Carol Lynch, president, U.S. and head of North America for Sandoz, discusses the supply challenges she’s observed in the biologics space throughout the current pandemic and the efforts biosimilar makers should be taking to meet patients’ needs and prepare for future supply disruptions.
|